Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Licensing Agreements 13
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Equity Offering 20
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 22
Halozyme Completes Public Offering Of Common Stock For US$83 Million 23
Halozyme Therapeutics Inc – Key Competitors 25
Halozyme Therapeutics Inc – Key Employees 26
Halozyme Therapeutics Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 06, 2018: Halozyme reports third quarter 2018 financial results 28
Aug 08, 2018: Halozyme reports second quarter 2018 results 30
May 10, 2018: Halozyme Reports First Quarter 2018 Results 31
Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results 32
Nov 07, 2017: Halozyme Reports Third Quarter 2017 Results 33
Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 35
May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 36
Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2018: Halozyme appoints Benjamin Hickey as Chief Commercial Officer 39
Product News 40
11/10/2017: Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors 40
10/24/2017: First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 Immunotherapy 41
10/16/2017: Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients 42
07/13/2017: Initiation Of Clinical Trial Collaboration Evaluating Halozyme’s PEGPH20 In Combination With Anti-PDL1 Immunotherapy 43
06/04/2017: Experimental drug makes some pancreatic cancers more vulnerable to chemo 44
05/31/2017: Clinical trial shows experimental drugs ability to knock down pancreatic cancers defense 46
03/30/2017: Halozyme Provides Update On SWOG Collaborative Group Clinical Study 48
01/09/2017: Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 49
Clinical Trials 50
Jun 28, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium 50
Jun 04, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 52
May 17, 2017: Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO 54
Apr 03, 2017: Halozyme’s PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Cancer Models 56
Jan 05, 2017: Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 58
Other Significant Developments 59
Jan 09, 2018: Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 12
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 13
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 14
Roche Enters into Licensing Agreement with Halozyme Therapeutics 15
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 16
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 17
Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 18
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 19
Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 20
Halozyme Therapeutics Completes Public Offering Of Shares For US$115 Million 22
Halozyme Completes Public Offering Of Common Stock For US$83 Million 23
Halozyme Therapeutics Inc, Key Competitors 25
Halozyme Therapeutics Inc, Key Employees 26
Halozyme Therapeutics Inc, Subsidiaries 27
List of Figures
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Halozyme Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Halozyme Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer